CY1120773T1 - Ενα συστημα παροχης φαρμακου - Google Patents

Ενα συστημα παροχης φαρμακου

Info

Publication number
CY1120773T1
CY1120773T1 CY181101075T CY181101075T CY1120773T1 CY 1120773 T1 CY1120773 T1 CY 1120773T1 CY 181101075 T CY181101075 T CY 181101075T CY 181101075 T CY181101075 T CY 181101075T CY 1120773 T1 CY1120773 T1 CY 1120773T1
Authority
CY
Cyprus
Prior art keywords
delivery system
core
intermediate layer
therapeutically active
medicine delivery
Prior art date
Application number
CY181101075T
Other languages
English (en)
Inventor
Heikki Lyytikäinen
Harri Jukarainen
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47666152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1120773(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of CY1120773T1 publication Critical patent/CY1120773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • External Artificial Organs (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα νέο σύστημα παροχής φαρμάκου για την ελεγχόμενη απελευθέρωση θεραπευτικώς δραστικών ουσιών σε προκαθορισμένο, ουσιαστικά σταθερό ρυθμό απελευθέρωσης για παρατεταμένο χρονικό διάστημα. Το σύστημα παροχής περιλαμβάνει τουλάχιστον έναν πυρήνα που περιλαμβάνει την/τις εν λόγω θεραπευτικώς δραστική(-ές) ουσία(-ες), τουλάχιστον μία μεμβράνη που περικλείει τον πυρήνα και ένα ενδιάμεσο στρώμα ουσιαστικά αδρανούς υλικού, όπου το ενδιάμεσο στρώμα εφαρμόζεται μεταξύ του πυρήνα και της μεμβράνης ή μεταξύ δύο στρωμάτων μεμβρανών.
CY181101075T 2012-01-23 2018-10-18 Ενα συστημα παροχης φαρμακου CY1120773T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20125069 2012-01-23
PCT/FI2013/050068 WO2013110856A1 (en) 2012-01-23 2013-01-22 A drug delivery system

Publications (1)

Publication Number Publication Date
CY1120773T1 true CY1120773T1 (el) 2019-12-11

Family

ID=47666152

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101075T CY1120773T1 (el) 2012-01-23 2018-10-18 Ενα συστημα παροχης φαρμακου

Country Status (39)

Country Link
US (1) US10500381B2 (el)
EP (1) EP2806893B1 (el)
JP (1) JP6236401B2 (el)
KR (1) KR102004014B1 (el)
CN (1) CN104144702B (el)
AR (1) AR089765A1 (el)
AU (1) AU2013213514B2 (el)
BR (1) BR112014017834B1 (el)
CA (1) CA2861947A1 (el)
CL (1) CL2014001935A1 (el)
CO (1) CO7020911A2 (el)
CR (1) CR20140358A (el)
CU (1) CU24431B1 (el)
CY (1) CY1120773T1 (el)
DK (1) DK2806893T3 (el)
DO (1) DOP2014000171A (el)
EA (1) EA032208B1 (el)
EC (1) ECSP14010605A (el)
ES (1) ES2691635T3 (el)
HK (1) HK1203802A1 (el)
HR (1) HRP20181707T1 (el)
IL (1) IL233599B (el)
LT (1) LT2806893T (el)
MX (1) MX355961B (el)
MY (1) MY172812A (el)
NZ (1) NZ627461A (el)
PE (1) PE20141818A1 (el)
PH (1) PH12014501654B1 (el)
PL (1) PL2806893T3 (el)
PT (1) PT2806893T (el)
RS (1) RS57911B1 (el)
SG (1) SG11201404032SA (el)
SI (1) SI2806893T1 (el)
TR (1) TR201815247T4 (el)
TW (1) TWI626951B (el)
UA (1) UA116197C2 (el)
UY (1) UY34583A (el)
WO (1) WO2013110856A1 (el)
ZA (1) ZA201406206B (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835495B2 (en) 2012-11-14 2020-11-17 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide material and methods of making and using the same
EP2982352B1 (en) * 2014-06-28 2018-10-03 Laboratorios Andrómaco S.A. Cervical pessary containing progesterone for prolonged, sustained and continuous release, used to prevent premature birth
US20200276110A1 (en) * 2015-12-21 2020-09-03 Bayer Oy A method of manufacturing a vaginal ring
WO2018202574A1 (en) 2017-05-04 2018-11-08 Bayer Oy Intravaginal drug delivery system, method for manufacturing such system and its use in gynecological therapies and contraception
EP3687495A1 (en) 2017-09-27 2020-08-05 Bayer Oy A method for modifying release of a therapeutically active agent from an elastomeric matrix
CN109954198B (zh) * 2017-12-25 2021-10-12 先健科技(深圳)有限公司 药物球囊及其制备方法
KR20210129090A (ko) * 2019-02-19 2021-10-27 파티클 사이언시스 인코포레이티드 구획화된 약물 전달 기기

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2054784T3 (es) * 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
NZ330726A (en) * 1998-06-18 2000-10-27 Dec Res Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
WO2001085132A1 (en) 2000-05-10 2001-11-15 Leiras Oy Drug delivery device, especially for the delivery of levonorgestrel
AU2002210580A1 (en) * 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
HUP0401438A3 (en) * 2001-08-31 2008-04-28 Schering Oy Drug delivery system
DE10209979A1 (de) 2002-03-07 2003-09-25 Ratiopharm Gmbh Arzneimittel mit Cholesterolspiegel-senkenden Wirkstoffen mit zeitverzögerter Wirkstofffreisetzung
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
ES2398318T3 (es) 2004-03-12 2013-03-15 Biodel, Inc. Composiciones de suministro de fármacos de acción rápida
PT1629844E (pt) 2004-07-13 2007-10-17 Bayer Schering Pharma Oy Sistema de distribuição a longo prazo com distribuição súbita inicial controlada
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
EP1833469A2 (en) 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US20060165776A1 (en) * 2005-08-31 2006-07-27 Ramesh Sesha Antidepressant oral pharmaceutical compositions
US8137327B2 (en) 2006-06-16 2012-03-20 Family Health International Vaginal drug delivery system and method
MX2009005364A (es) * 2006-11-20 2009-06-05 Organon Nv Sistema de suministro de farmaco con forma helicoidal.
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
FI121000B (fi) 2008-11-19 2010-06-15 Bayer Schering Pharma Oy Intravaginaalinen antojärjestelmä ja menetelmä sen valmistamiseksi
JP2014508131A (ja) * 2010-12-27 2014-04-03 ダウ コーニング コーポレーション 薬物送達分散体及びそれから形成されるフィルム

Also Published As

Publication number Publication date
MX355961B (es) 2018-05-07
PT2806893T (pt) 2018-11-09
CA2861947A1 (en) 2013-08-01
EA032208B1 (ru) 2019-04-30
US10500381B2 (en) 2019-12-10
DOP2014000171A (es) 2014-08-15
UA116197C2 (uk) 2018-02-26
US20140350488A1 (en) 2014-11-27
IL233599B (en) 2019-07-31
CN104144702B (zh) 2018-03-06
SG11201404032SA (en) 2014-08-28
SI2806893T1 (sl) 2019-02-28
CN104144702A (zh) 2014-11-12
KR20140127262A (ko) 2014-11-03
BR112014017834B1 (pt) 2021-05-18
PH12014501654A1 (en) 2014-10-13
AU2013213514B2 (en) 2017-07-13
EP2806893A1 (en) 2014-12-03
EA201400834A1 (ru) 2014-12-30
MX2014008906A (es) 2014-08-26
MY172812A (en) 2019-12-12
JP2015504083A (ja) 2015-02-05
BR112014017834A2 (el) 2017-06-20
JP6236401B2 (ja) 2017-11-22
AR089765A1 (es) 2014-09-17
PL2806893T3 (pl) 2019-01-31
KR102004014B1 (ko) 2019-07-25
TW201343204A (zh) 2013-11-01
CO7020911A2 (es) 2014-08-11
AU2013213514A1 (en) 2014-08-07
HK1203802A1 (en) 2015-11-06
RS57911B1 (sr) 2019-01-31
BR112014017834A8 (pt) 2017-07-11
CU20140094A7 (es) 2014-11-27
CL2014001935A1 (es) 2015-04-10
HRP20181707T1 (hr) 2019-02-22
IL233599A0 (en) 2014-08-31
PE20141818A1 (es) 2014-12-18
CU24431B1 (es) 2019-07-04
EP2806893B1 (en) 2018-07-18
ZA201406206B (en) 2019-06-26
ES2691635T3 (es) 2018-11-28
TWI626951B (zh) 2018-06-21
UY34583A (es) 2013-09-02
NZ627461A (en) 2016-07-29
CR20140358A (es) 2014-11-17
LT2806893T (lt) 2018-12-10
PH12014501654B1 (en) 2014-10-13
TR201815247T4 (tr) 2018-11-21
DK2806893T3 (en) 2018-11-05
ECSP14010605A (es) 2015-12-31
WO2013110856A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
CY1120773T1 (el) Ενα συστημα παροχης φαρμακου
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
AU2017268840A1 (en) Materials architecture for gastric residence systems
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
CY1113075T1 (el) Μοσχευματα αποφραξης δακρυϊκου σημειου και μεθοδοι παροχης θεραπευτικων παραγοντων
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
CY1116638T1 (el) Διαδερμικο θεραπευτικο συστημα για την χορηγηση μιας δραστικης ουσιας
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
CY1122492T1 (el) Φορεας για χορηγηση στον στοματικο βλεννογονο, ειδικα για υπογλωσσια χορηγηση, δραστικων φυσιολογικα ουσιων
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112018077541A2 (pt) formulações orais gastrorretentivas e usos das mesmas
EP3415141A4 (en) ULTRAVIOLET-CURING HYDROGEL RESIN AND HYDROGEL FOR TRANSDERMAL DELIVERY, AND CATAPLASM AGENT COMPRISING THE SAME
UA114101C2 (xx) Трансдермальна терапевтична система для введення фентанілу або його аналога
CY1124303T1 (el) Διαδερμικο θεραπευτικο συστημα με καλυπτικη ταινια, που περιλαμβανει δυο συγκολλητικα στρωματα
MX2019001884A (es) Entrega local sostenida de farmacos que incluyen antibioticos.
EP3441080A4 (en) PHARMACEUTICAL COMPOSITION FOR HEALING WOUNDS CONTAINING SUBSTANCE P
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
CY1120812T1 (el) Υποκατεστημενα παραγωγα αζασπειρο(4.5)δεκανιου
EP3880175A4 (en) TEMPERATURE-REGULATING TRANSDERMAL DRUG DELIVERY SYSTEM
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
DK3453390T3 (da) Farmaceutisk sammensætning indeholdende polymeriseret lægemiddel
MX2020004250A (es) Composicion farmaceutica de liberacion sostenida.
CY1120443T1 (el) Yποκατεστημενα παραγωγα αζασπειρο(4.5)δεκανιου
EP3900710A4 (en) LAYERED TRANSDERMAL DRUG DELIVERY SYSTEM WITH IBUPROFEN OR A STRUCTURAL ANALOGUE THEREOF